Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...
Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...
Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling). Dissolve under tongue; do not chew or swallow. The use of ...
Concomitant moderate or strong CYP3A4 inducers: initially 4mg/day at bedtime. Elderly or hepatic impairment: max frequency for dose increase is every 2 weeks; mild: max 6mg/day; moderate ...
Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company developing best-in-class small molecule inducers of immunogenic cell death (ICD), a novel oncology immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback